MAR001
MAR001 is a fully humanised inhibitory antibody of ANGPTL4.(3) In studies of non-human primates with hypertriglyceridaemia, single-dose MAR001 treatment reduced plasma TG by up to 58%, non-high-density lipoprotein cholesterol by 38%, apoB by 30%, and remnant cholesterol (RC) by 59%.(3) In safety studies, MAR001 was well tolerated without clinically adverse findings.(3) Animals fed a high saturated fat diet (HSFD), designed to mimic a typical human western diet, showed minimal to moderate foamy macrophage formation in mesenteric lymph nodes (MLN) but these histological findings did not progress to degeneration, necrosis, inflammation, fibrosis, or other reactive changes.(3)View key references >
- Kersten S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism. J Lipid Res. 2021;62:100150.
- Gusarova V, O'Dushlaine C, Teslovich TM et al. Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. Nat Commun. 2018 Jun 13;9(1):2252.
- Cummings BB, Bouchard PR, Milton MN et al. An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates. 2025 Jul;117:105748.
